The Taiwan government deserves congratulations for its recent enactment of landmark legislation establishing a Patent Linkage system for pharmaceutical products, a mechanism designed to prevent infringing drugs from being licensed while an original medication still holds a valid patent in this market. Credit goes both to the executive branch agencies that ushered through this initiative…

Should the current target-expenditure system be extended? When the Taiwan government five years ago was working on how to revamp the National Health Insurance (NHI) program to help ensure its long-term sustainability, one of the new measures it adopted was a suggestion from the pharmaceutical industry that had been broached in AmCham Taipei’s 2010 Taiwan…

Strengthening protection of intellectual property rights (IPR) is crucial to attracting investment in Taiwan’s pharmaceutical sector. In order to better protect IPR for innovative products, the Pharmaceutical Committee of the American Chamber of Commerce in Taipei recommends completing the legislative process for Patent Linkage and Data Exclusivity. Patent Linkage prevents regulatory authorization of generic medicines…

“Robust intellectual property (IP) protection is vital for biopharmaceutical innovation,” stresses a recently released report from Geneva Network, a UK-based public policy research and advocacy organization specializing in international intellectual property, health, and trade issues. The report – written by Geneva Network researcher Jack Ellis, a former Asia-Pacific editor of Intellectual Asset Management magazine –…

A visiting delegation urges early passage of Patent Linkage legislation. During a recent visit to Taipei, a six-member delegation from the Washington, DC-based Pharmaceutical Research and Manufacturers of America (PhRMA) urged Taiwan’s legislature to give early attention to pending bills to strengthen intellectual property protection for pharmaceuticals. Passage of the proposed amendments to the Pharmaceutical…

Companies have been punished for disseminating disease-awareness information. In Taiwan, as in the rest of the world with the lone exceptions of the United States and New Zealand, pharmaceutical companies are prohibited from advertising prescription drugs directly to consumers. The main rationale for that approach is the belief that decisions on what drug to prescribe…

A National Drug Policy Forum brought wide discussion but few conclusions. The Ministry of Health and Welfare (MOHW) in early February convened a one-day National Drug Policy Forum (originally scheduled to be held in December 2014), bringing together representatives from the various stakeholders: government, hospitals and other healthcare providers, the pharmaceutical industry (both originals and…

animal cosmetic testing white mice

How to protect animals while also ensuring consumer safety? A bill currently before the Legislative Yuan would prohibit the manufacture and sale in Taiwan of cosmetics products tested on animals when alternative methods are available. It would authorize the Taiwan Food and Drug Administration (TFDA) to designate the alternative methods specified for industry use. If…